Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

• Disease Name: Craniofacial Anomalies and Anterior Segment Dysgenesis Syndrome (CAASDS; VSX1/RINX homeobox gene, A256S CVC-domain change; OMIM 614195)
• MONDO ID: MONDO:0013618 (if available)
• Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Craniofacial Anomalies and Anterior Segment Dysgenesis Syndrome (CAASDS; VSX1/RINX homeobox gene, A256S CVC-domain change; OMIM 614195) covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

• What is the disease? Provide a concise overview.
• What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
• What are the common synonyms and alternative names?
• Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

• Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
• Risk Factors:

  Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

• Genetic risk factors (causal variants, susceptibility loci, modifier genes)
• Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
• Protective Factors:

  Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

• Genetic protective factors (protective variants, modifier alleles)
• Environmental protective factors (diet, lifestyle, exposures that reduce risk)
• Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

  Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

• Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

  Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

• Pathogenic Variants:
• Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
• Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
• Variant type/class (missense, frameshift, nonsense, splice-site, structural)
• Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
• Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
• Functional consequences (loss of function, gain of function, dominant negative)
• Modifier Genes: Genes that modify disease severity or expression
• Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

  Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

• Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

  Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

• Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

  Search first: CDC databases, WHO, PubMed, NHANES

• Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

  Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Present this section as an ordered causal chain first, then the detail below. Open with a numbered sequence of mechanistic steps running from the initiating lesion (mutation, exposure, infection) to the clinical manifestation, one step per line, each naming what it causes next. State the causal verb explicitly ("leads to", "results in") and say where a step is inferred rather than demonstrated. Where the mechanism branches, show the branch. The categories below are a checklist of what to cover within those steps, not the organizing structure — a step may draw on several of them, and a category may contribute to several steps.

• Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

  Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

• Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

  Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

• Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

  Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

• Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

  Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

• Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

  Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

• Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

  Search first: PubMed, Gene Ontology, Reactome

• Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

  Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

• Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Molecular Profiling (if available):
• Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
• Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
• Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
• Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
• Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
• Advanced Technologies (if applicable):
• Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
• Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
• Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
• Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

• Organ Level:
• Primary organs directly affected
• Secondary organ involvement (complications, secondary effects)
• Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

  Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

• Tissue and Cell Level:
• Specific tissue types affected (epithelial, connective, muscle, nervous)
• Specific cell populations targeted (with Cell Ontology terms)

  Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

• Subcellular Level:
• Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

  Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

• Localization:
• Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
• Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

• Onset:
• Typical age of onset (congenital, pediatric, adult, geriatric)
• Onset pattern (acute, subacute, chronic, insidious)

  Search first: OMIM, Orphanet, HPO, PubMed

• Progression:
• Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
• Progression rate (rapid, slow, variable)
• Disease course pattern (episodic, relapsing-remitting, progressive, stable)
• Disease duration (self-limited, chronic lifelong)

  Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

• Patterns:
• Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
• Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

• Epidemiology:
• Prevalence (cases per 100,000 at given time)
• Incidence (new cases per 100,000 per year)

  Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

• For Genetic Etiology:
• Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
• Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
• Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
• Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
• Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
• Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
• Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
• Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
• Population Demographics:
• Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
• Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
• Geographic distribution of specific variants
• Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
• Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

• Clinical Tests:
• Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
• Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
• Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
• Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
• Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
• Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
• Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
• Genetic Testing:

  Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

• Overview of recommended genetic testing approach
• Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
• Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
• Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
• Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
• Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
• Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
• FISH > Search first: ClinVar, cytogenetics databases, PubMed
• Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
• Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
• Omics-Based Diagnostics (if applicable):
• RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
• Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
• Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
• Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
• Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
• Clinical Criteria:
• Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
• Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
• Screening:
• Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

• Survival and Mortality:
• Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
• Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
• Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
• Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
• Morbidity and Function:
• Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
• Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
• Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
• Disease Course:
• Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
• Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
• Prediction:
• Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
• Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

• Pharmacotherapy:
• Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
• Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
• Advanced Therapeutics:
• Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
• Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
• RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
• Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
• Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
• Surgical and Interventional:
• Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
• Supportive and Rehabilitative:
• Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
• Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
• Experimental:
• Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
• Treatment Outcomes:
• Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
• Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
• Treatment Strategy:
• Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
• Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
• Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

13. Prevention

• Prevention Levels:
• Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
• Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
• Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
• Immunization: Vaccine strategies (if applicable)

  Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

• Screening and Early Detection:
• Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
• Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
• Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
• Behavioral Interventions: Lifestyle modifications to reduce risk

  Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

• Counseling: Genetic counseling (risk assessment, family planning guidance)

  Search first: NSGC resources, ACMG guidelines, GeneReviews

• Public Health:
• Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
• Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
• Prophylaxis: Preventive medications or procedures

  Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

• Taxonomy: Species affected (with NCBI Taxon identifiers)

  Search first: NCBI Taxonomy

• Breed: Specific breeds affected (with VBO identifiers if applicable)

  Search first: VBO (Vertebrate Breed Ontology)

• Gene: Orthologous genes in other species (with NCBI Gene IDs)

  Search first: NCBI Gene

• Natural Disease:
• Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
• Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
• Comparative Biology:
• Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
• Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
• Transmission (if applicable):
• Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
• Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

• Model Types:
• Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
• Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
• Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
• Genetic Models:
• Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
• Model Characteristics:
• Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
• Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
• Applications:
• Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
• Resources:
• Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

• Cite primary literature (PMID preferred) for all mechanistic and clinical claims
• Prioritize recent reviews and landmark papers
• Include direct quotes from abstracts where possible to support key statements
• Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Craniofacial Anomalies and Anterior Segment Dysgenesis Syndrome (CAASDS)

Executive summary

CAASDS is an exceptionally rare, proposed Mendelian developmental syndrome defined principally by one 2004 report linking a heterozygous VSX1 (formerly RINX) missense variant, p.Ala256Ser (A256S) in the conserved CVC domain, with craniofacial abnormalities, corneal/anterior-segment changes, empty sella, and abnormal retinal and auditory electrophysiology. The principal primary citation is Mintz-Hittner et al., Ophthalmology 111:828–836, published April 2004, PMID: 15051220 (PubMed). Current Open Targets data map this phenotype to MONDO:0013618 and identify VSX1 as its leading associated target, but most database records ultimately reuse the same publication rather than providing independent replication. Consequently, the syndrome and especially the pathogenicity of A256S should be treated as limited-evidence assertions, not as a well-validated gene–disease relationship. (OpenTargets Search: craniofacial anomalies and anterior segment dysgenesis syndrome-VSX1)

No new human CAASDS cohort, natural-history study, prevalence estimate, disease-specific treatment, or interventional trial was identified for 2023–2024. The main recent advance is a 2023 zebrafish vsx1/vsx2 double-knockout study showing retinal-network redundancy; it is informative about VSX biology but is neither a VSX1-only model nor an A256S model. (joaquin2023mutationofvsx pages 1-3, joaquin2023mutationofvsx pages 7-10)

Table: This table maps the sparse human and model-organism evidence for CAASDS to suggested ontology concepts. It highlights the major limitations: dependence on one defining human report, uncertain A256S functional evidence, and lack of epidemiologic or therapeutic studies.

Evidence-quality framework

• Human clinical evidence: one defining report/pedigree, PMID 15051220; no independently replicated CAASDS series was retrieved.
• Database evidence: MONDO/Open Targets, EVA/ClinVar-linked record RCV000005562, and a Genomics England “amber” monoallelic annotation. These are not independent patient cohorts. The EVA entry is a missense record with “no assertion criteria provided.” (OpenTargets Search: craniofacial anomalies and anterior segment dysgenesis syndrome-VSX1)
• Model evidence: mouse VSX1 studies and a 2023 zebrafish vsx1/vsx2 double knockout support retinal bipolar-cell biology, but do not validate human A256S.
• Inference: CVC-domain dysfunction plausibly affects DNA binding, but direct experimental evidence retrieved for this principle concerns mainly VSX2, not VSX1 A256S. (zou2012vsx2controlseye pages 2-4, zou2012vsx2controlseye pages 4-4)

Because the original article’s full text/abstract was not retrievable through the supplied literature tools, exact patient counts, patient-level measurements, segregation details, and verbatim quotations from PMID 15051220 cannot be certified here. The report therefore avoids inventing frequencies or measurements.

1. Disease information

Definition and identifiers

CAASDS is a proposed congenital multisystem developmental disorder combining craniofacial dysmorphism, anterior ocular abnormalities—particularly corneal endothelial change—and neuro-sensory physiological abnormalities. Its defining publication title is itself clinically descriptive: “VSX1 (RINX) mutation with craniofacial anomalies, empty sella, corneal endothelial changes, and abnormal retinal and auditory bipolar cells.” (joaquin2023mutationofvsx pages 41-43, nejabat2017vsx1andsod1 pages 6-6)

Open Targets currently recognizes MONDO_0013618 and gives VSX1 an association score of 0.5304, based on literature, genetic, variant, and model evidence. This numerical score is a platform evidence-integration score—not penetrance, pathogenic probability, or clinical validity. A much weaker ZNF469 association (0.0516) derives from model evidence and should not be interpreted as a second established CAASDS gene. (OpenTargets Search: craniofacial anomalies and anterior segment dysgenesis syndrome-VSX1)

Synonyms: craniofacial anomalies–anterior segment dysgenesis syndrome; CAASDS; VSX1/RINX-associated craniofacial and ocular syndrome. The source information is primarily aggregated disease-level information derived from a small published family/case report, not longitudinal EHR evidence or a registry cohort.

2. Etiology

Causal factor and genetic risk

The proposed cause is a germline, monoallelic VSX1 missense substitution, p.Ala256Ser, in the conserved CVC domain. Database annotations describe a monoallelic autosomal/pseudoautosomal, non-imprinted requirement, consistent with autosomal-dominant inheritance, but the relevant Genomics England assessment is “amber.” (OpenTargets Search: craniofacial anomalies and anterior segment dysgenesis syndrome-VSX1)

The evidence does not establish whether A256S acts through haploinsufficiency, dominant-negative activity, altered DNA-binding specificity, or another gain-of-function mechanism. No retrieved A256S-specific assay demonstrated altered stability, nuclear localization, DNA binding, transcriptional repression, or developmental phenotype. Studies of VSX-family CVC substitutions indicate that the CVC domain can support high-affinity DNA binding, but the detailed experiments were performed with VSX2, and their results cannot simply be assigned to VSX1. (zou2012vsx2controlseye pages 2-4, zou2012vsx2controlseye pages 4-4)

Other risk, protective, and gene–environment factors

No reproducible modifier gene, susceptibility locus, protective allele, environmental exposure, toxin, infection, parental-age effect, lifestyle factor, or gene–environment interaction has been reported specifically for CAASDS. Family history would be relevant if dominant inheritance is confirmed, but numerical recurrence risks depend on confirming variant pathogenicity and parental status.

No protective intervention can prevent a constitutional developmental variant from arising. Prenatal avoidance of alcohol, smoking, teratogenic medication, and infection remains general obstetric care, not CAASDS-specific prevention.

3. Phenotypes

The following phenotype list is conservative. Frequencies cannot be estimated from the available evidence.

VSX1 is expressed later than VSX2 in retinal development and is restricted in mice to subsets of differentiated ON and OFF cone bipolar cells. Therefore, bipolar-cell dysfunction is biologically coherent. It does not, however, explain the craniofacial, corneal, or sellar findings without additional evidence. (joaquin2023mutationofvsx pages 1-3)

No behavioral, psychiatric, metabolic, hematologic, immune, cardiovascular, renal, or gastrointestinal phenotype has been established. There are no CAASDS-specific EQ-5D, SF-36, PROMIS, or other quality-of-life data. Plausible functional effects include reduced visual/hearing performance and burdens from repeated ophthalmic or audiologic care, but these remain unquantified.

4. Genetic and molecular information

Gene

VSX1 encodes a paired-like homeobox transcription factor containing a DNA-binding homeodomain and adjacent conserved CVC domain. VSX1 and VSX2 are paralogs with related regulatory modules and reported recognition of the DNA motif TAATTAGC, but they differ in developmental timing and functional importance. VSX2 is prominent in early retinal progenitors; VSX1 is associated more with later cone bipolar-cell differentiation. (joaquin2023mutationofvsx pages 1-3)

Suggested annotations include DNA-binding transcription-factor activity, sequence-specific DNA binding, regulation of transcription by RNA polymerase II, retinal development, and bipolar-cell differentiation.

Variant interpretation

• Reported change: p.Ala256Ser (A256S).
• Class: missense variant.
• Origin: presumed constitutional/germline in the reported family; no evidence supports a somatic event.
• Region: conserved CVC domain.
• Disease record: RCV000005562.
• Current caution: the retrieved EVA record supplies no assertion criteria, and modern literature notes that pathogenicity of reported VSX1 CVC variants has been uncertain. (zou2012vsx2controlseye pages 2-4, OpenTargets Search: craniofacial anomalies and anterior segment dysgenesis syndrome-VSX1)

A current laboratory should normalize the variant against the exact MANE Select transcript and genome assembly before reporting an HGVS cDNA coordinate. No cDNA coordinate, rsID, gnomAD frequency, TOPMed frequency, or ancestry-stratified frequency was verified in the retrieved evidence; none should be inferred from “A256S” alone.

Under ACMG/AMP principles, the historical phenotype/segregation report may contribute case-level or segregation evidence, while location in a conserved functional domain may contribute supporting evidence. However, absent verified population rarity, independent affected families, and A256S-specific functional studies, an unqualified “pathogenic” designation is not adequately supported by the evidence retrieved here. Contemporary reassessment could reasonably remain VUS/uncertain, depending on current database and transcript-specific data.

No confirmed modifier genes, CAASDS-specific methylation signature, chromatin disorder, copy-number variant, translocation, inversion, aneuploidy, or mitochondrial defect has been reported.

5. Environmental information

CAASDS is proposed to be genetic. No toxin, radiation exposure, pollution source, occupation, smoking, alcohol use, diet, exercise pattern, medication, bacterial infection, viral infection, fungal infection, or parasite has been implicated. Environmental teratogens can independently produce craniofacial and ocular abnormalities and therefore belong in the differential diagnosis, but they are not established cofactors for VSX1-associated CAASDS.

6. Mechanism and pathophysiology

Ordered causal chain

1. A germline VSX1 p.Ala256Ser substitution in the CVC domain is proposed to lead to altered VSX1 molecular function. This initiating genotype–function step is inferred, not directly demonstrated for A256S.
2. Altered CVC/homeodomain cooperation is inferred to lead to abnormal DNA binding or target-gene regulation. VSX2 experiments support the general CVC-domain principle, but are indirect evidence for VSX1. (zou2012vsx2controlseye pages 2-4, zou2012vsx2controlseye pages 4-4)
3. Abnormal transcriptional control in retinal cone bipolar-cell precursors is inferred to lead to impaired terminal differentiation or physiology. Mammalian expression and knockout observations make this branch biologically plausible. (joaquin2023mutationofvsx pages 1-3)
4. Bipolar-cell dysfunction leads to abnormal retinal signal processing and electroretinographic findings, potentially causing visual impairment.
5. A parallel auditory developmental branch is proposed to lead to abnormal auditory electrophysiology, but its VSX1-expressing cell population and molecular route were not established in the retrieved evidence.
6. A separate, poorly defined embryonic craniofacial/anterior-segment branch is proposed to lead to craniofacial dysmorphism, corneal endothelial change, and empty sella. This connection is clinical association rather than a demonstrated developmental pathway.

Cellular and molecular detail

The best-supported VSX1-relevant cell type is the retinal bipolar neuron, particularly cone bipolar-cell subsets. Suggested Cell Ontology concepts are retinal bipolar neuron, ON-bipolar neuron, OFF-bipolar neuron, cone retinal bipolar cell, retinal progenitor cell, photoreceptor cell, and Müller glial cell.

The 2023 zebrafish study supplies the latest functional and molecular-profiling evidence. CRISPR loss of both vsx1 and vsx2 produced severe visual impairment and bipolar-cell depletion; precursors were rerouted toward photoreceptor or Müller-glial fates, yet neural-retina specification persisted and microphthalmia was absent. Its abstract states: “Our observations point to genetic redundancy as an important mechanism sustaining the integrity of the retinal specification network.” (joaquin2023mutationofvsx pages 1-3)

ATAC-seq found 1,564 differentially accessible regions, but only 5% of genes near altered regions were differentially expressed. Among core retinal-network genes tested by qPCR, significant changes were limited to rx2 and lhx2b. Müller-glial markers increased, whereas amacrine-cell differentiation and spinal V2a/V2b interneuron density were largely preserved. These data imply compensatory network robustness rather than a simple linear loss-of-function cascade. (joaquin2023mutationofvsx pages 7-10)

Suggested GO biological-process terms include retinal development, retinal bipolar-cell differentiation, cell-fate specification, nervous-system development, regulation of transcription, chromatin organization, visual perception, and sensory-system development. Suggested GO cellular components include nucleus, chromatin, and transcription-regulator complex. No CAASDS-specific metabolic, lipidomic, proteomic, immune, inflammatory, oxidative-stress, apoptotic, or fibrosis mechanism has been demonstrated.

No human A256S transcriptomic, single-cell, spatial-transcriptomic, proteomic, metabolomic, lipidomic, CRISPR-screen, iPSC, or organoid profile was identified.

7. Anatomical structures affected

Primary reported organs: eye, craniofacial structures, sellar region, and auditory system.

• Eye: anterior segment and corneal endothelium; functionally, neural retina/retinal bipolar circuitry.
• Craniofacial complex: exact bones and soft tissues were not retrievable.
• Sellar region: empty sella; pituitary endocrine dysfunction was not established.
• Auditory system: physiological abnormality reported, but exact cochlear/brainstem localization is uncertain.

Suggested UBERON concepts are eye, anterior segment of eyeball, cornea, corneal endothelium, retina, inner nuclear layer of retina, pituitary fossa/sella turcica, craniofacial region, inner ear, and auditory system. Suggested subcellular localization is the nucleus, consistent with a homeobox transcription factor. Laterality—unilateral, bilateral, or asymmetric—cannot be assigned reliably from retrieved evidence.

8. Temporal development

The syndrome is best regarded as congenital/developmental, because craniofacial and anterior-segment malformations arise during embryogenesis. Empty sella may likewise reflect developmental anatomy. The ages at detection of retinal and auditory physiological abnormalities are unavailable.

There is no validated stage model, progression rate, remission pattern, or longitudinal natural history. Structural dysgenesis is expected to be stable, whereas corneal endothelial dysfunction, vision, and hearing could change over time; this is a clinical possibility, not documented CAASDS natural history. Embryonic craniofacial and ocular development constitutes the critical biological period, while infancy and childhood are the practical windows for detecting treatable visual or hearing impairment.

9. Inheritance and population

The historical and database framing is monoallelic/autosomal dominant, but penetrance and expressivity cannot be quantified. The platform annotation explicitly permits autosomal or pseudoautosomal monoallelic inheritance and is graded amber. (OpenTargets Search: craniofacial anomalies and anterior segment dysgenesis syndrome-VSX1)

No evidence establishes age-dependent penetrance, anticipation, germline mosaicism, founder effect, consanguinity contribution, carrier frequency, ethnicity enrichment, geographic clustering, sex ratio, or age distribution. Prevalence and incidence are unknown; “ultra-rare” is descriptive rather than a measured statistic. Database evidence counts must not be counted as separate patients because several records point back to PMID 15051220.

For counseling, a confirmed heterozygous pathogenic variant in an affected parent would conventionally confer a 50% transmission probability per pregnancy, but the probability of the full CAASDS phenotype cannot be estimated without penetrance data. That calculation should not be applied until current variant classification and familial segregation are reviewed.

10. Diagnostics

Clinical evaluation

There are no consensus CAASDS diagnostic criteria. A reasonable evaluation for a suspected patient includes:

1. Detailed dysmorphology and three-generation pedigree.
2. Slit-lamp examination, gonioscopy when indicated, corneal pachymetry and endothelial specular microscopy.
3. Visual acuity/refraction and retinal examination.
4. Full-field ERG where bipolar-cell dysfunction is suspected.
5. Formal audiometry plus auditory brainstem response/electrophysiology when indicated.
6. Pituitary/sellar MRI if clinically justified; endocrine testing driven by symptoms or imaging findings.

These are phenotype-directed applications, not validated CAASDS criteria.

Genetic testing strategy

• Preferred: a comprehensive anterior-segment dysgenesis/craniofacial-ocular panel or exome/genome sequencing with CNV analysis, because A256S causality is not firmly established and phenocopies are numerous.
• VSX1 sequencing: appropriate when the phenotype closely resembles the original report, but should include deletion/duplication analysis where technically available.
• Familial testing: essential for segregation, penetrance assessment, and reclassification.
• WES/WGS: useful when panel testing is negative or syndromic features extend beyond the reported spectrum.
• CMA: useful when multiple congenital anomalies suggest a copy-number disorder.
• Karyotype/FISH: not first-line unless a structural chromosome abnormality is suspected.
• Mitochondrial and repeat-expansion testing have no established CAASDS indication.

No validated RNA-seq, proteomic, metabolomic, epigenomic, liquid-biopsy, or biochemical biomarker exists.

Differential diagnosis

Important alternatives include other genetically defined anterior-segment dysgenesis disorders involving PAX6, PITX2, FOXC1, CYP1B1, FOXE3, PITX3, and VSX2; Axenfeld–Rieger spectrum; Peters anomaly; posterior polymorphous corneal dystrophy; congenital hereditary endothelial dystrophy; syndromic craniosynostosis/craniofacial disorders; and teratogenic embryopathies. VSX2-associated microphthalmia must not be conflated with VSX1-associated CAASDS: VSX2 has a stronger experimentally demonstrated role in early eye organogenesis. (zou2012vsx2controlseye pages 2-4, zou2012vsx2controlseye pages 4-4)

There is no population newborn screen. Cascade testing is appropriate only after a clinically meaningful familial variant has been confirmed. Prenatal or preimplantation testing requires careful counseling about uncertain pathogenicity and penetrance.

11. Outcome and prognosis

No survival curve, mortality rate, life-expectancy estimate, disability-adjusted burden, or standardized quality-of-life result exists. The reported phenotype does not itself establish reduced lifespan. Expected morbidity is primarily sensory and ophthalmic, with possible craniofacial or endocrine implications depending on the individual.

Potential complications include impaired vision from anterior-segment/corneal disease or retinal signal-processing dysfunction, hearing impairment, and amblyopia during childhood. Empty sella warrants clinical attention to pituitary function, but no CAASDS-specific endocrine complication rate is known. Prognostic biomarkers and validated risk models are absent.

Recovery depends on manifestation: congenital structural abnormalities do not biologically “remit,” but refractive, corneal, hearing, endocrine, and developmental consequences may be mitigated. No treatment-response percentages are available.

12. Treatment and real-world implementation

There is no disease-modifying drug, gene therapy, cell therapy, RNA therapy, immunotherapy, or genotype-targeted treatment for CAASDS. No relevant CAASDS-specific interventional trial or NCT identifier was found in the tool search.

Management is multidisciplinary and manifestation-directed:

• Ophthalmology: refractive correction, amblyopia prevention, low-vision support, corneal and glaucoma surveillance; corneal surgery or transplantation only for standard clinical indications.
• Audiology/otolaryngology: hearing aids, assistive devices, or cochlear implantation according to measured deficit—not genotype alone.
• Craniofacial care: surgical, dental, speech, or psychosocial intervention according to anatomy and function.
• Endocrinology: evaluate and replace pituitary hormones only when deficiency is documented.
• Genetics: variant reinterpretation, segregation testing, and reproductive counseling.

Suggested NCIt intervention concepts include ophthalmologic examination, electroretinography, audiometry, auditory brainstem response, magnetic-resonance imaging, genetic counseling, molecular genetic testing, corrective lenses, hearing aid, low-vision rehabilitation, and supportive care. No CAASDS-specific pharmacogenomic interaction is known.

13. Prevention

Primary prevention: none for an inherited constitutional variant. Vaccination, diet, or lifestyle change has no demonstrated effect on CAASDS occurrence.

Secondary prevention: early ophthalmic and hearing assessment may prevent avoidable amblyopia, delayed language development, or educational impact. This is extrapolated standard care rather than trial-proven CAASDS prevention.

Tertiary prevention: surveillance and timely management of corneal, visual, auditory, craniofacial, or endocrine complications.

Genetic counseling should discuss the limited gene–disease evidence, uncertain penetrance, reproductive options, prenatal diagnosis, and preimplantation genetic testing. Such testing is technically possible after familial-variant confirmation, but its predictive value is limited if A256S remains a VUS.

14. Other species and natural disease

No naturally occurring veterinary equivalent of human CAASDS, breed predisposition, VBO term, zoonotic transmission, or cross-species infectious susceptibility was identified. The disorder is not transmissible or zoonotic.

Orthologous vsx1 genes occur across vertebrates. Comparative studies support evolutionary conservation of VSX-family homeodomain/CVC architecture and retinal expression, but regulatory weight differs substantially between mammals, zebrafish, and medaka. (joaquin2023mutationofvsx pages 7-10, joaquin2023mutationofvsx pages 1-3)

Suggested taxa for comparative annotation are Homo sapiens (NCBI Taxonomy 9606), Mus musculus (10090), and Danio rerio (7955).

15. Model organisms

Mouse

Vsx1-deficient mouse work supports roles in retinal cone bipolar-cell differentiation and photopic circuitry. Modern summaries indicate that Vsx1 mutation does not substantially disrupt early retinal specification, even on a Vsx2-mutant background, emphasizing that VSX1 and VSX2 are not functionally interchangeable. Abnormal ERGs have been reported in mice and in some human VSX1 contexts. (joaquin2023mutationofvsx pages 1-3)

Strength: mammalian retinal physiology and cell-type relevance.
Limitation: knockout does not reproduce A256S, and retrieved evidence does not establish craniofacial, corneal-endothelial, sellar, or auditory recapitulation.

Zebrafish—latest development

Letelier et al. used CRISPR-Cas9 to generate a vsx1/vsx2 double knockout, assessed with histology, ERG, optokinetic behavior, RNA-seq, qPCR, and ATAC-seq. The abstract reports “severe visual impairment and bipolar cells depletion” with precursors rerouted to photoreceptor or Müller-glial fates, but says “neural retina is properly specified and maintained” and mutants “do not display microphthalmia.” (joaquin2023mutationofvsx pages 1-3, joaquin2023mutationofvsx pages 33-36)

Quantitatively, 1,564 chromatin-accessibility regions changed, yet only 5% of nearby genes changed expression, demonstrating compensatory network robustness. (joaquin2023mutationofvsx pages 7-10)

Strength: recent functional, electrophysiological, cellular, and multi-omic model.
Limitation: simultaneous loss of vsx1 and vsx2 prevents attribution to vsx1 alone; complete knockout differs fundamentally from A256S; no craniofacial/sellar syndrome was modeled.

Needed models

The decisive experiments would be a human VSX1 A256S knock-in in retinal organoids/iPSC-derived bipolar cells and an orthologous animal knock-in, coupled to protein localization, DNA-binding, transcriptional-reporter, single-cell RNA-seq/ATAC-seq, corneal-endothelial differentiation, ERG, auditory electrophysiology, and craniofacial assessment. Such models were not identified.

Overall expert assessment

CAASDS remains a provisional, extremely sparsely documented syndrome. The phenotype is memorable and biologically compatible with a retinal transcription factor in part, but current support is dominated by one 2004 report and derivative database entries. The key unresolved issue is not whether VSX1 participates in retinal bipolar-cell biology—it does—but whether A256S is truly pathogenic and sufficient to produce the full craniofacial–ocular–sellar–auditory syndrome. Modern VSX biology highlights redundancy, species differences, and the danger of transferring VSX2 CVC-domain results directly to VSX1. (joaquin2023mutationofvsx pages 1-3, zou2012vsx2controlseye pages 2-4)

For knowledge-base purposes, the most defensible representation is: VSX1 p.Ala256Ser–associated CAASDS, limited human evidence; monoallelic inheritance proposed; penetrance and mechanism unknown; variant-specific functional validation absent.

Key references

1. Mintz-Hittner HA et al. “VSX1 (RINX) mutation with craniofacial anomalies, empty sella, corneal endothelial changes, and abnormal retinal and auditory bipolar cells.” Ophthalmology. April 2004;111:828–836. PMID 15051220. https://pubmed.ncbi.nlm.nih.gov/15051220/ (joaquin2023mutationofvsx pages 41-43, nejabat2017vsx1andsod1 pages 6-6)
2. Letelier J et al. “Mutation of vsx genes in zebrafish highlights the robustness of the retinal specification network.” eLife. 2023; preprint DOI/URL retrieved: https://doi.org/10.1101/2022.01.20.477122. (joaquin2023mutationofvsx pages 7-10, joaquin2023mutationofvsx pages 1-3)
3. Zou C, Levine EM. “Vsx2 Controls Eye Organogenesis and Retinal Progenitor Identity Via Homeodomain and Non-Homeodomain Residues Required for High Affinity DNA Binding.” PLoS Genetics. September 2012. https://doi.org/10.1371/journal.pgen.1002924. This is indirect VSX-family mechanistic evidence, not direct CAASDS validation. (zou2012vsx2controlseye pages 2-4, zou2012vsx2controlseye pages 4-4)
4. Nejabat M et al. “VSX1 and SOD1 Mutation Screening in Patients with Keratoconus in the South of Iran.” Journal of Ophthalmic & Vision Research. April 2017;12:135–140. https://doi.org/10.4103/jovr.jovr_97_16. This illustrates broader uncertainty and non-replication around VSX1 corneal-disease associations rather than confirming CAASDS. (nejabat2017vsx1andsod1 pages 6-6)

References

1. (OpenTargets Search: craniofacial anomalies and anterior segment dysgenesis syndrome-VSX1): Open Targets Query (craniofacial anomalies and anterior segment dysgenesis syndrome-VSX1, 2 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

2. (joaquin2023mutationofvsx pages 1-3): Joaquín Letelier, Lorena Buono, María Almuedo-Castillo, Jingjing Zang, Constanza Mounieres, Sergio González-Díaz, Rocío Polvillo, Estefanía Sanabria-Reinoso, Jorge Corbacho, Ana Sousa-Ortega, Ruth Diez Del Corral, Stephan C F Neuhauss, and Juan R Martínez-Morales. Mutation of vsx genes in zebrafish highlights the robustness of the retinal specification network. eLife, Jan 2023. URL: https://doi.org/10.1101/2022.01.20.477122, doi:10.1101/2022.01.20.477122. This article has 21 citations and is from a domain leading peer-reviewed journal.

3. (joaquin2023mutationofvsx pages 7-10): Joaquín Letelier, Lorena Buono, María Almuedo-Castillo, Jingjing Zang, Constanza Mounieres, Sergio González-Díaz, Rocío Polvillo, Estefanía Sanabria-Reinoso, Jorge Corbacho, Ana Sousa-Ortega, Ruth Diez Del Corral, Stephan C F Neuhauss, and Juan R Martínez-Morales. Mutation of vsx genes in zebrafish highlights the robustness of the retinal specification network. eLife, Jan 2023. URL: https://doi.org/10.1101/2022.01.20.477122, doi:10.1101/2022.01.20.477122. This article has 21 citations and is from a domain leading peer-reviewed journal.

4. (zou2012vsx2controlseye pages 2-4): Changjiang Zou and Edward M. Levine. Vsx2 controls eye organogenesis and retinal progenitor identity via homeodomain and non-homeodomain residues required for high affinity dna binding. Sep 2012. URL: https://doi.org/10.1371/journal.pgen.1002924, doi:10.1371/journal.pgen.1002924. This article has 85 citations and is from a domain leading peer-reviewed journal.

5. (joaquin2023mutationofvsx pages 41-43): Joaquín Letelier, Lorena Buono, María Almuedo-Castillo, Jingjing Zang, Constanza Mounieres, Sergio González-Díaz, Rocío Polvillo, Estefanía Sanabria-Reinoso, Jorge Corbacho, Ana Sousa-Ortega, Ruth Diez Del Corral, Stephan C F Neuhauss, and Juan R Martínez-Morales. Mutation of vsx genes in zebrafish highlights the robustness of the retinal specification network. eLife, Jan 2023. URL: https://doi.org/10.1101/2022.01.20.477122, doi:10.1101/2022.01.20.477122. This article has 21 citations and is from a domain leading peer-reviewed journal.

6. (nejabat2017vsx1andsod1 pages 6-6): M. Nejabat, Payam Naghash, Hassan Dastsooz, S. Mohammadi, M. Alipour, and M. Fardaei. Vsx1 and sod1 mutation screening in patients with keratoconus in the south of iran. Journal of Ophthalmic & Vision Research, 12:135-140, Apr 2017. URL: https://doi.org/10.4103/jovr.jovr_97_16, doi:10.4103/jovr.jovr_97_16. This article has 24 citations and is from a peer-reviewed journal.

7. (zou2012vsx2controlseye pages 4-4): Changjiang Zou and Edward M. Levine. Vsx2 controls eye organogenesis and retinal progenitor identity via homeodomain and non-homeodomain residues required for high affinity dna binding. Sep 2012. URL: https://doi.org/10.1371/journal.pgen.1002924, doi:10.1371/journal.pgen.1002924. This article has 85 citations and is from a domain leading peer-reviewed journal.

8. (joaquin2023mutationofvsx pages 33-36): Joaquín Letelier, Lorena Buono, María Almuedo-Castillo, Jingjing Zang, Constanza Mounieres, Sergio González-Díaz, Rocío Polvillo, Estefanía Sanabria-Reinoso, Jorge Corbacho, Ana Sousa-Ortega, Ruth Diez Del Corral, Stephan C F Neuhauss, and Juan R Martínez-Morales. Mutation of vsx genes in zebrafish highlights the robustness of the retinal specification network. eLife, Jan 2023. URL: https://doi.org/10.1101/2022.01.20.477122, doi:10.1101/2022.01.20.477122. This article has 21 citations and is from a domain leading peer-reviewed journal.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Unresolved references

These identifiers did not resolve to a record and may be fabricated. A lookup that failed for transport reasons is indistinguishable from one that failed because the record does not exist, so spot-check before acting on them:

• DOI:10.4103/jovr.jovr_97_16 (5 mentions) - Identifier did not resolve to a record

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• MONDO:0013618 (4 mentions) - the report calls it "if available", "MONDO"; MONDO calls it craniofacial anomalies and anterior segment dysgenesis syndrome

Terms named inconsistently

The report gives these identifiers more than one name of its own:

• MONDO:0013618 - called "if available", "MONDO"